A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2019-03-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in
combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists
of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006
dose expansion), and Part C (SC-006 and ABBV-181 combination escalation and expansion). Part
A (dose regimen finding) will involve dose escalation and possible dose interval modification
to define the maximum tolerated dose (MTD) and/or recommended Part B dose and schedule. Part
B (dose expansion) will enroll additional participants who will be treated with a study drug
dose at or below the MTD determined in Part A. Part C is dose escalation of SC-006 and fixed
dose of ABBV-181 in combination. Recommended dose cohort of SC-006 with ABBV-181 will be
expanded.